Merck & Co., Inc. (MRK), Wednesday announced that the company has entered into an exclusive global license deal with China-based Hansoh Pharma to develop, manufacture and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
The company also intends to evaluate HS-10535 and its potential to provide additional cardiometabolic benefits beyond weight reduction.
Under the terms of the deal, Hansoh Pharma will receive an upfront payment of $112 million, milestone payments of upto $1.9 billion, and royalties on sales.
Meanwhile, Merck will record a pre-tax charge of $112 million, or $0.04 a share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
During the pre-market hours, Merck's stock is trading at $101.35, up 1.29 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.